Inversago Pharma develops peripherally acting CB1 receptor blockers to treat metabolic conditions such as diabetic kidney disease, obesity, and non-alcoholic steatohepatitis. Their lead program, INV-202, is currently in Phase 2 trials, targeting the complications associated with diabetes and obesity.
Funding
Funding not disclosed
Founders
Product
Problem
Metabolic and fibrotic diseases, including diabetic kidney disease, obesity, and non-alcoholic steatohepatitis, present significant therapeutic challenges. Current treatments often fail to adequately address the underlying pathophysiology and complications associated with these conditions.
Solution
Inversago Pharma develops peripherally acting CB1 receptor blockers as a novel therapeutic approach for metabolic and fibrotic diseases. By selectively blocking CB1 receptors outside the central nervous system, Inversago's compounds aim to modulate key biological processes involved in these conditions without the adverse effects associated with centrally acting CB1 inhibitors. Their lead program, INV-202, is currently in Phase 2 clinical trials for diabetic kidney disease and obesity, demonstrating the potential to improve patient outcomes by targeting the complications of diabetes and obesity. Inversago is also developing compounds for fibrotic diseases such as pulmonary fibrosis, fibrotic liver and kidney diseases, and systemic sclerosis.
Target Audience
The primary target audience includes patients suffering from metabolic diseases such as diabetic kidney disease, obesity, and non-alcoholic steatohepatitis, as well as those with fibrotic diseases.
Features
- INV-202: A peripherally acting CB1 receptor blocker in Phase 2 clinical trials for diabetic kidney disease and obesity.
- Selective CB1 receptor blockade: Targets peripheral CB1 receptors to avoid central nervous system side effects.
- Pipeline of innovative CB1r blockers: Designed to address a range of metabolic and fibrotic diseases.
- Focus on complications of diabetes and obesity: Including diabetic kidney disease, non-alcoholic steatohepatitis, and hyperlipidemia.
- Development programs for fibrotic indications: Such as progressive fibrosis
- interstitial lung disease.